PURE BIOSCIENCE, INC.
Close on Oct 19, 2026
- Market cap
- $7.33M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Oct 28, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2026 Ended Apr 30, 2026 | Jun 15, 2026 | During market hours | $506.00K | $-0.01 | – |
| Q2 FY2026 Ended Jan 31, 2026 | Mar 17, 2026 | After market close | $444.00K | $-0.01 | – |
| Q1 FY2026 Ended Oct 31, 2025 | Dec 15, 2025 | During market hours | $708.00K | $0.00 | – |
| Q4 FY2025 Ended Jul 31, 2025 | Oct 29, 2025 | During market hours | – | – | – |
| Q3 FY2025 Ended Apr 30, 2025 | Jun 16, 2025 | During market hours | $491.00K | $-0.01 | – |
| Q2 FY2025 Ended Jan 31, 2025 | Mar 17, 2025 | During market hours | $391.00K | $-0.01 | – |
| Q1 FY2025 Ended Oct 31, 2024 | Dec 16, 2024 | During market hours | $556.00K | $-0.01 | – |
| Q4 FY2024 Ended Jul 31, 2024 | Oct 29, 2024 | During market hours | – | – | – |
| Q3 FY2024 Ended Apr 30, 2024 | Jun 14, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jan 31, 2024 | Mar 18, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Oct 31, 2023 | Dec 14, 2023 | During market hours | – | – | – |
Press releases
Announcements Pure Bioscience filed with the SEC
Bioscience Reports Fiscal Third Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal Second Quarter 2026
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal First Quarter 2026
Results of operations · EX-99.1 to Form 8-K
CAJON, CA – PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal Third Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal Second Quarter 2025
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal First Quarter 2025
Results of operations · EX-99.1 to Form 8-K
CAJON, CA – PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal Third Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal Second Quarter 2024
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal First Quarter 2024
Results of operations · EX-99.1 to Form 8-K
on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal 2023 Third Quarter
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal 2023 Second Quarter
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal First Quarter 2023
Results of operations · EX-99.1 to Form 8-K
on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal 2022 Third Quarter
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal 2022 Second Quarter
Results of operations · EX-99.1 to Form 8-K
Bioscience Reports Fiscal First Quarter 2022
Results of operations · EX-99.1 to Form 8-K
on Business and PURE’s SDC-Based Antimicrobial Food Safety Solutions
Results of operations · EX-99.1 to Form 8-K